696949, 95% CI = −3.656832 to 5.050731, P = 0.6797). The subgroup analyses of African or European studies demonstrated a significantly higher prevalence of homozygous MTHFR C677T mutation in cirrhotic patients with PVT than in those without PVT (Table 5). One Asian study also demonstrated a trend toward a higher prevalence of homozygous MTHFR C677T mutation in cirrhotic patients with PVT than in those without PVT, but the difference was not statistically significant. Four studies compared the prevalence of heterozygous MTHFR C677T mutation

between cirrhotic patients with and without PVT. The heterogeneity among studies was not significant (I2 = 0%, Maraviroc price P = 0.70). Using a fixed-effects model, the prevalence of heterozygous buy Ceritinib MTHFR C677T mutation was similar between the two groups (OR = 1.25, 95% CI = 0.84–1.85, P = 0.27) (Fig. 4d).

Regardless of any regions, the subgroup analyses did not demonstrate any significant difference in the prevalence of heterozygous MTHFR C677T mutation between cirrhotic patients with and without PVT (Table 5). Only two studies compared the prevalence of hyperhomocysteinemia between cirrhotic patients with and without PVT. The heterogeneity among studies was significant (I2 = 93%, P = 0.0002). Using a random-effects model, the prevalence of hyperhomocysteinemia was similar between the two groups (OR = 1.48, 95% CI = 0.12–18.63, P = 0.76) (Fig. 5d). Sensitivity analyses were not performed due to a very small number of included studies (n = 2). Regardless of any regions, the subgroup analyses demonstrated a significantly higher prevalence of hyperhomocysteinemia

in cirrhotic patients with PVT than in those without PVT (Table 5). Three studies compared the plasma homocysteine level between cirrhotic patients with and without PVT. The heterogeneity among studies was significant (I2 = 93.8%, P < 0.00001). Using a random-effects model, the plasma homocysteine level was similar between the two groups (WMD = 4.17, MCE 95% CI = −2.29 to 10.63, P = 0.21) (Fig. 6d). In the subgroup analysis, one Asian study demonstrated a significantly higher homocysteine level in cirrhotic patients with PVT than in those without PVT. Contrarily, the subgroup analysis of European studies did not demonstrate any significant difference between them (Table 5). One European study demonstrated that the prevalence of total MTHFR C677T mutation was significantly higher in patients with PVT than in those without PVT (OR = 24.75, 95% CI = 2.71–225.62, P = 0.004), but the prevalence of homozygous and heterozygous MTHFR C677T mutation were similar between the two groups (OR = 6.43, 95% CI = 0.67–61.47, P = 0.11; and OR = 3.71, 95% CI = 0.97–14.23, P = 0.06, respectively).[33] One European study demonstrated that the prevalence of homozygous MTHFR C677T mutation was similar between hepatocellular carcinoma patients with and without PVT (OR = 2.10, 95% CI = 0.84–5.25, P = 0.11).